Scalper1 News
Momenta Pharmaceuticals’ (MNTA) stock dropped 8% Thursday after UBS downgraded it to sell, saying the company’s recent good news has already been priced into the stock. Analyst Marc Goodman wrote that last month’s launch of Momenta’s and partner Novartis’ (NVS) generic version of Teva Pharmaceutical’s (TEVA) blockbuster Copaxone should drive near-term earnings growth, but he says the doubling of the stock price this year has also been driven by Scalper1 News
Scalper1 News